期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

对抗菌药物防突变浓度及突变选择窗两概念的探讨与思索 被引量：3

Discussion and considerations on the mutant prevention concentration and mutant selective window
下载PDF
导出
摘要 防突变浓度(MPC)及突变选择窗(MSW)是由ZhaoX等近几年提出的防耐药变异的新概念。结合文献,本文对MPC及MSW几个相关问题进行了探讨,并简单综述了抗菌药物防耐药变异应用策略。 The mutant prevention concentration （MPC） and mutant selective window （MSW） were new conceptive theories of resistance mutantion preventation which were raised by Zhao X and Drlica K et al. In this paper, the conceptions of MPC and MSW and some could related issues were discussed. Finally how to prevent resistance mutantion was reviewed.
作者 黄瀚 刘世坤
机构地区 湖南省医药学校 中南大学湘雅医学院附三医院药剂科
出处 《中国临床药理学与治疗学》 CAS CSCD 2008年第1期21-24,共4页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 防突变浓度 突变选择窗 最低抑菌浓度 耐药变异 mutant prevention concentration mutant selective window minimum inhibitory concentration resistance mutantion
分类号 R969 [医药卫生—药理学]
  • 相关文献

参考文献12

  • 1Baquero F, Negri MC. Strategies to minimize the development of antibiotic resistance[ J]. J Chemother, 1997,9(Suppl 1) :29 - 37.
  • 2Dong Y,. Zhao X, Domagala J, et al. Effect of fluoroquilonone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus [ J ]. Antimicro Agents Chemother, 1999,43(7):1756- 1758.
  • 3Zhao X. Restricting the selection of antibiotic resistant mutants: a general strategy derived from fluoroquinolones studies [J]. Clin Infect Dis, 2001,33(Suppl 3):S147- 156.
  • 4Drlica K. A strategy for fighting antibiotic resistance [ J ]. ASM News, 2001,67(1):27- 33.
  • 5Rowe-Magnus DA, Guerout AM, Mazel .D. Bacterial resistance evolution by recruitment of super-integron gene cassettes[J]. Mol Microbiol, 2002;43(6) : 1657.
  • 6Dong Y, Zhao X, Kreiswirth BN, et al. Mutant prevention concentration as a measure of antibiotic potency::studies with clinical isolates of mycobacterium tuberculosis[J]. Antimicrob Agents hemother, 2000,44(9) :2581 - 2584.
  • 7Zhao J, Dong Y, Zhao X, et al. Selection of antibiotic resistant bacterial mutants: allelic diversity among fluoroquilonone resistant mutantions[J]. J Infect Dis, 2002,182(2) :517 - 525.
  • 8Zhao X, Drlica K. Restricting the selection of antibiotic resistant mutant bacteria: measurement and potential use of the mutant selection window[J]. J Infect Dis, 2002, 185(4): 561 - 565.
  • 9袁斌,刘贵昌,徐磊.铜离子杀菌剂灭活SRB的研究[J].腐蚀与防护,2005,26(5):187-188. 被引量：6
  • 10Chastre J,Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator2 associated pneumonia in adults: a randomized trial [ J ]. JAMA, 2003, 290 (19) :2588 - 2598.

二级参考文献16

  • 1Perry C, Chendrasekhar A, Moorman DW, et al. Ventilator associated pneumonia:therapy based protected specimen brushing versus trachea aspirate data. Chest, 1999,116 (4) :278 S-281 S.
  • 2JRS. The Japanese Respiratory Society guidelines for management of hospital-acquired pneumonia. Respir,2004,9 ( 9 ): S30-S34.
  • 3Gruson D, Hilbert G,Vargas F, et al. Strategy of antibiotic rotation:longterm effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med, 2003,31(7) :1908-1914.
  • 4Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit.Crit Care Med,2001,29(6) :1101-1108.
  • 5Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections:getting it right the first time. Drugs, 2003,63 (20):2157-2168.
  • 6Masterton R, Drusano G, Paterson DL, et al. Appropriate antimicrobial treatment in nosocomial infections-the clinical challenges. J Hosp Infeet,2003,55 ( Suppl 1 ): 1-12.
  • 7Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults:a randomized trial. JAMA ,2003,290(19) :2588-2598.
  • 8Dennesen PJ ,van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilatorassociated pneumonia. Am J Respir Crit Care Med, 2001,163 ( 6 ):1371-1375.
  • 9Healthcare Infection Control Practices Advisory Committee. Guidelines for preventing health-care-associated pneumonia ,2003 recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care,2004,49 ( 8 ) :926-939.
  • 10Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med,2000,132(8) :621-630.

共引文献27

同被引文献55

  • 1李朝霞,刘又宁.细菌耐药突变选择窗理论与抗菌药物合理应用[J].中国药学杂志,2006,41(16):1201-1205. 被引量：31
  • 2Zhao X, Drlica K. Rcstrieting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolones studies[J]. Clin Infect Dis,2001,33 (Suppl):5147-5156.
  • 3Drlica K. A strategy for fighting antibiotic resistance[J].ASM News,2001,67:27-33.
  • 4Dong Y, Zhao X, Domagala J, et al. Effect of fluoroquinolone concentration on selection of resistant mutants of mycobacterium bovis BCG and staphylococcus aureus[J].Antimicrobial Agents AND Chemotherapy, 1999,43 (7) : 1756-1758.
  • 5Zhao X,Drlica K. Restricting the selection of antibiotic-resistant mutant bacteria:measurement and potential use of the mutant selection window[J]. The Journal of Infectious Diseases, 2002,185:561-565.
  • 6Cui J, Liu Y, Wang R et al. The mutant selection window demonstrated in rabbits infected with staphylococcus aureus[J].Infect Dis,2006,194:1601-1608.
  • 7Zhanel G, Mayer M, Laing N, el al. Mutant prevention concentrations of levoflnxacin alone and in combination with azithro mycin, ceftazidime, colistin ( polymyxin E ), rneropenem, piperacillin tazobactam, and tobramycin against pseudomonas aeruginosa [J]. Antimicrohial Agents AND Chemotherapy, 2006,50(6) :2228-2230.
  • 8Hesje CK, Borsos SD, Blondeau JM. Benzalkonium Chloride enhances anlihaclerial actixity of gatifloxzcin and reduces its propensity to select for fluoroquinolone-resistant strains[J].Journal of Ocular Pharmacology and Therapeutics, 2009, 25 (4) :329-331.
  • 9Sindelar G, Zhao X, Liew A, el al. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria[J].Antimicrobial Agents AND Chemotherapy,2000, 44(12) :3337-3343.
  • 10Zhao. Clarification of MPC and the mutant selection window concept[J]. Journal of Antimicrobial Chemotherapy, 2003,52: 731.

引证文献3

二级引证文献2

中国临床药理学与治疗学
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部